Evaluation of the Prognostic Value of Hierarchical Cytogenetic Risk Group Classification in Newly Diagnosed AML and in BMT in First Remission
| . | Outcome . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Patients Hierarchical Risk Group . | CR Rate Hierarchical Risk Group . | Relapse Risk at 3 yr % (SE) Hierarchical Risk Group . | Survival at 3 yr % (SE) Hierarchical Risk Group . | |||||||||
| Favorable . | Intermediate . | Adverse . | Favorable . | Intermediate . | Adverse . | Favorable . | Intermediate . | Adverse . | Favorable . | Intermediate . | Adverse . | |
| Age group | ||||||||||||
| 0-14 yr | 88 | 219 | 33 | 94 | 92 | 88 | 32 (5.4)5-150 | 40 (3.6) | 61 (9.2) | 78 (4.4)5-151 | 55 (3.4) | 42 (8.6) |
| 15-34 yr | 141 | 273 | 47 | 905-150 | 91 | 70 | 32 (4.3)5-151 | 45 (3.4) | 72 (8.8) | 66 (4.0)5-151 | 51 (3.0) | 19 (5.8) |
| 35+ yr | 148 | 580 | 83 | 895-151 | 81 | 49 | 31 (4.4)5-151 | 53 (2.5) | 92 (4.5) | 65 (3.9)5-151 | 37 (2.0) | 5 (2.4) |
| Type of leukemia | ||||||||||||
| De novo | 363 | 996 | 134 | 915-151 | 87 | 66 | 32 (2.7)5-151 | 47 (1.8) | 78 (4.7) | 69 (2.4)5-151 | 46 (1.6) | 17 (3.3) |
| Secondary | 14 | 76 | 29 | 935-150 | 72 | 52 | 19 (2.7)5-151 | 62 (1.8) | 67 (12.2) | 79 (11.0)5-150 | 25 (5.0) | 14 (6.4) |
| Treatment in first remission5-152 | ||||||||||||
| Chemotherapy | 242 | 626 | 69 | 38 (3.3)5-151 | 55 (2.1) | 76 (5.6) | 76 (2.7)5-151 | 48 (2.0) | 25 (5.4) | |||
| Allogeneic BMT | 50 | 148 | 13 | 8 (4.3)5-151 | 18 (3.6) | 77 (14.1) | 62 (9.6)5-151 | 65 (4.5) | 13 (9.0) | |||
| Autologous BMT | 50 | 131 | 18 | 20 (6.0)5-150 | 35 (4.5) | 65 (11.8) | 78 (8.3)5-151 | 56 (4.6) | 46 (12.1) | |||
| . | Outcome . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Patients Hierarchical Risk Group . | CR Rate Hierarchical Risk Group . | Relapse Risk at 3 yr % (SE) Hierarchical Risk Group . | Survival at 3 yr % (SE) Hierarchical Risk Group . | |||||||||
| Favorable . | Intermediate . | Adverse . | Favorable . | Intermediate . | Adverse . | Favorable . | Intermediate . | Adverse . | Favorable . | Intermediate . | Adverse . | |
| Age group | ||||||||||||
| 0-14 yr | 88 | 219 | 33 | 94 | 92 | 88 | 32 (5.4)5-150 | 40 (3.6) | 61 (9.2) | 78 (4.4)5-151 | 55 (3.4) | 42 (8.6) |
| 15-34 yr | 141 | 273 | 47 | 905-150 | 91 | 70 | 32 (4.3)5-151 | 45 (3.4) | 72 (8.8) | 66 (4.0)5-151 | 51 (3.0) | 19 (5.8) |
| 35+ yr | 148 | 580 | 83 | 895-151 | 81 | 49 | 31 (4.4)5-151 | 53 (2.5) | 92 (4.5) | 65 (3.9)5-151 | 37 (2.0) | 5 (2.4) |
| Type of leukemia | ||||||||||||
| De novo | 363 | 996 | 134 | 915-151 | 87 | 66 | 32 (2.7)5-151 | 47 (1.8) | 78 (4.7) | 69 (2.4)5-151 | 46 (1.6) | 17 (3.3) |
| Secondary | 14 | 76 | 29 | 935-150 | 72 | 52 | 19 (2.7)5-151 | 62 (1.8) | 67 (12.2) | 79 (11.0)5-150 | 25 (5.0) | 14 (6.4) |
| Treatment in first remission5-152 | ||||||||||||
| Chemotherapy | 242 | 626 | 69 | 38 (3.3)5-151 | 55 (2.1) | 76 (5.6) | 76 (2.7)5-151 | 48 (2.0) | 25 (5.4) | |||
| Allogeneic BMT | 50 | 148 | 13 | 8 (4.3)5-151 | 18 (3.6) | 77 (14.1) | 62 (9.6)5-151 | 65 (4.5) | 13 (9.0) | |||
| Autologous BMT | 50 | 131 | 18 | 20 (6.0)5-150 | 35 (4.5) | 65 (11.8) | 78 (8.3)5-151 | 56 (4.6) | 46 (12.1) | |||
OS and RR are quoted at 3 years, as relatively small numbers in some subgroups would restrict the reliability of 5-year values.
P < .01.
P < .001: P values are for log rank test (OS and RR) or Mantel Haenszel test for trend (CR rate) in effect of hierarchical risk group within age group, type of leukemia, or treatment in first remission.
Chemotherapy patients are censored at BMT. Survival is from the date of BMT in the transplanted groups and from CR in the chemotherapy group. Percentages may not add to 100 because of rounding.